ALXO

ALX Oncology Holdings

Fundamental data last updated:March 30, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/14/26

Business Summary

ALX Oncology Holdings is a clinical-stage biotechnology company focused on developing therapies for cancer and other serious diseases. The company works on advancing drug candidates through research and clinical trials to address unmet medical needs in oncology.

VALUATION

P/E

-

Market Cap ($M USD)

$267

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

10.3

EV / EBITDA

-2.3

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.90

Next Year EPS Growth Estimate

-$0.61

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-391.40%

Operating Margin

-

Debt-to-Equity

0.4

Piotroski F-Score

1

Altman Z-Score

-17.4

Return on Invested Capital (ROIC)

-130.70%%

Current Ratio

2.1

Quick Ratio

Gainseekers Quantitative Analysis

Summary

ALX Oncology Holdings is a Nasdaq-listed biotechnology company with a market capitalization of $267 million. The company is currently unprofitable, with an EPS of -2.3 and a projected EPS next year of -$1.90, alongside a deeply negative operating margin of -391.40%. It trades at a price-to-book ratio of 10.3 and offers a TTM yield of 0.4, with its next earnings report due on 05/14/26.

AI Exposure / Tech Reliance

As a biotechnology company in the healthcare sector, its performance is primarily tied to drug development and clinical progress rather than artificial intelligence or advanced technology platforms. Its value proposition appears more dependent on scientific and clinical execution than on AI-driven innovation.

The Bull Case

The projected improvement in EPS from -2.3 to -$1.90 suggests potential progress toward reducing losses. With a small market cap of $267 million and a consensus rating of 1.10%, there may be upside if operational performance stabilizes or improves.

The Bear Case

The company’s operating margin of -391.40% highlights significant operational inefficiencies and ongoing losses. A high price-to-book ratio of 10.3 combined with negative earnings and negative sales growth next year of -$0.61 increases financial risk.

Market Sentiment & Smart Money

Short Interest %

1.10%

Analyst Consensus

1.5

Average Analyst Price Target

$4.60

Institutional Ownership %

40.30%

1-Year Beta

1

Insider Buying % (6 Mo)

1.20%%

Distance to 52-Week High

76.50%%

Distance to 52-Week Low

503.70%%